PDX-Derived Liver Cancer Organoid Model

Liver is a metabolic and detoxifying organ of the body. Due to the complexity of its microenvironment, it is challenging to find a representative model to explore the occurrence, development, and treatment of liver diseases. In recent years, liver cancer is common and difficult to cure, which further drives up the research demand for liver cancer models. Creative Biolabs, a leading biotech company in preclinical drug development, has established new 3D models such as PDX-derived liver cancer organoids to support global customers’ projects for new drug development against liver cancer.

Shortcomings of Common Models

During the past years, 2D or 3D cell cultures and animal models have been extensively used in research on liver cancer. However, in practical application, they present many shortcomings. The former can’t reflect the individualized liver physiology and pathology because of the relatively constant genetic information. On the other hand, they lack the tumor environment. The latter including patient-derived xenografts (PDXs) has a low success rate, high expenditures, and big resource waste. In short, they are not optimal models for the investigate of liver cancer and need to be optimized further.

Advantages of PDX-derived Liver Cancer Organoid Models

At present, the PDX-derived organoid (PDXO) technology is in a period of rapid development and displays many obvious advantages over conventional models in the liver cancer research field.

• Stably maintain the genetic information, physiological and pathological state of autologous tissue.
• Reproduce the TME of self-tissue (including extracellular factors) and immunogenicity on the surface of hepatocytes.
• Preserve the similar structure and protein expression of original tumors in vitro in the long-term passage.
• Easier to be established with high success rate as compared with PDX models.

Applications

On the whole, the PDXO technology displays great potential to provide favorable conditions for individualized treatment and large-scale drug screening. Integrated with emerging biotechnologies, liver cancer PDXO models will create an excellent platform for studying the mechanism of the occurrence and pathogenesis of tumors, and boost new drug discovery.

Fig.1 Applications of PDX-derived liver cancer organoid models. (Creative Biolabs)

Related Services

As a reputable biology corporation, the business of Creative Biolabs has expanded to the 3D biology field and will continuously dig and enrich our service scope. Until now, a variety of ex vivo physiological models including 3D organoid models have been added to our service portfolio. With rich experience in preclinical drug discovery and professional scientific team, our goal is to provide you with exceptional service to ensure the successful completion of your research project. Ready to make more contributions to human health, we look forward to offering high-quality PDX-derived liver cancer organoid models and related services listed below. Please feel free to contact us for more details.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model